National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

• Published in: Journal of clinical lipidology Vol. 8; no. 5; pp. 473 - 488
• Main Authors: Jacobson, Terry A., Ito, Matthew K., Maki, Kevin C., Orringer, Carl E., Bays, Harold E., Jones, Peter H., McKenney, James M., Grundy, Scott M., Gill, Edward A., Wild, Robert A., Wilson, Don P., Brown, W. Virgil
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2014
• Subjects: Adult; Atherogenic cholesterol; Atherosclerotic cardiovascular disease; Cardiovascular; Clinical recommendations; Coronary heart disease; Disease Progression; Dyslipidemia; Dyslipidemias - drug therapy; Dyslipidemias - epidemiology; Dyslipidemias - metabolism; Dyslipidemias - therapy; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Life Style; Lipoproteins; Lipoproteins - metabolism; Low-density lipoprotein cholesterol; Risk Assessment; Societies, Medical; Atherogenic cholesterol; Lipoproteins; Atherosclerotic cardiovascular disease; Dyslipidemia; Clinical recommendations; Coronary heart disease; Low-density lipoprotein cholesterol
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2014.07.007

Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol—non–high-density lipoprotein cholesterol and low-density lipoprotein cholesterol—as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia.